Gilead Ventures into 'In Vivo' Cell Treatment with $350 Million Acquisition of Interius

Gilead Ventures into ‘In Vivo’ Cell Treatment with $350 Million Acquisition of Interius

Gilead Ventures into 'In Vivo' Cell Treatment with $350 Million Acquisition of Interius